178 related articles for article (PubMed ID: 34749742)
1. Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma.
Li Z; Yang G; Han L; Wang R; Gong C; Yuan Y
J Nanobiotechnology; 2021 Nov; 19(1):360. PubMed ID: 34749742
[TBL] [Abstract][Full Text] [Related]
2. Homotypic cell membrane-camouflaged biomimetic PLGA nanoparticle loading triptolide for the treatment of hepatocellular carcinoma.
Li Z; Lan J; Wu Y; Ding Y; Zhang T
Drug Deliv; 2024 Dec; 31(1):2354687. PubMed ID: 38823413
[TBL] [Abstract][Full Text] [Related]
3. Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy.
Zheng Y; Kong F; Liu S; Liu X; Pei D; Miao X
Drug Deliv; 2021 Dec; 28(1):2033-2043. PubMed ID: 34569906
[TBL] [Abstract][Full Text] [Related]
4. Self-Amplified pH/ROS Dual-Responsive Co-Delivery Nano-System with Chemo-Photodynamic Combination Therapy in Hepatic Carcinoma Treatment.
Huang Y; Wu S; Li J; He C; Cheng Y; Li N; Wang Y; Wu Y; Zhang J
Int J Nanomedicine; 2024; 19():3737-3751. PubMed ID: 38699684
[TBL] [Abstract][Full Text] [Related]
5. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer.
Zheng S; Wang J; Ding N; Chen W; Chen H; Xue M; Chen F; Ni J; Wang Z; Lin Z; Jiang H; Liu X; Wang L
J Nanobiotechnology; 2021 Nov; 19(1):381. PubMed ID: 34802453
[TBL] [Abstract][Full Text] [Related]
6. Triptolide Inhibits Invasion and Tumorigenesis of Hepatocellular Carcinoma MHCC-97H Cells Through NF-κB Signaling.
Wang H; Ma D; Wang C; Zhao S; Liu C
Med Sci Monit; 2016 May; 22():1827-36. PubMed ID: 27239780
[TBL] [Abstract][Full Text] [Related]
7. Novel CD44-targeting and pH/redox-dual-stimuli-responsive core-shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis.
Shi J; Ren Y; Ma J; Luo X; Li J; Wu Y; Gu H; Fu C; Cao Z; Zhang J
J Nanobiotechnology; 2021 Jun; 19(1):188. PubMed ID: 34162396
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
9. A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer.
Yalikong A; Li XQ; Zhou PH; Qi ZP; Li B; Cai SL; Zhong YS
Int J Nanomedicine; 2021; 16():2323-2335. PubMed ID: 33776436
[TBL] [Abstract][Full Text] [Related]
10. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
[TBL] [Abstract][Full Text] [Related]
11. Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis.
Zhang X; Wu L; Xu Y; Yu H; Chen Y; Zhao H; Lei J; Zhou Y; Zhang J; Wang J; Peng J; Jiang L; Sheng H; Li Y
Cancer Lett; 2020 Jul; 481():32-44. PubMed ID: 32246956
[TBL] [Abstract][Full Text] [Related]
12. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms.
Zhang YQ; Shen Y; Liao MM; Mao X; Mi GJ; You C; Guo QY; Li WJ; Wang XY; Lin N; Webster TJ
Nanomedicine; 2019 Jan; 15(1):86-97. PubMed ID: 30244085
[TBL] [Abstract][Full Text] [Related]
13. Targeted drug-loaded peptides induce tumor cell apoptosis and immunomodulation to increase antitumor efficacy.
Li H; Zhang P; Yuan X; Peng S; Yang X; Li Y; Shen Z; Bai J
Biomater Adv; 2024 Jun; 160():213852. PubMed ID: 38636118
[TBL] [Abstract][Full Text] [Related]
14. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Alsaied OA; Sangwan V; Banerjee S; Krosch TC; Chugh R; Saluja A; Vickers SM; Jensen EH
Surgery; 2014 Aug; 156(2):270-9. PubMed ID: 24953273
[TBL] [Abstract][Full Text] [Related]
16. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
17. Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics.
Yang M; Gu Y; Yang D; Tang X; Liu J
J Nanobiotechnology; 2017 Dec; 15(1):88. PubMed ID: 29202753
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumour effects of triptolide plus 10-hydroxycamptothecin onbladder cancer.
Wang T; Ding Y; Yang Y; Wang Z; Gao W; Li D; Wei J; Sun Y
Biomed Pharmacother; 2019 Jul; 115():108899. PubMed ID: 31063955
[TBL] [Abstract][Full Text] [Related]
19. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma.
Ling D; Xia H; Park W; Hackett MJ; Song C; Na K; Hui KM; Hyeon T
ACS Nano; 2014 Aug; 8(8):8027-39. PubMed ID: 25093274
[TBL] [Abstract][Full Text] [Related]
20. γ-Cyclodextrin metal-organic framework as a carrier to deliver triptolide for the treatment of hepatocellular carcinoma.
Li Z; Yang G; Wang R; Wang Y; Wang J; Yang M; Gong C; Yuan Y
Drug Deliv Transl Res; 2022 May; 12(5):1096-1104. PubMed ID: 33860448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]